Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
James Degregori
University of Colorado Denver, Department: Biochemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
Mitotherapeutix
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Dr. James V. DeGregori, PhD has a significant financial interest due to his role as an advisory board member and equity owner with the start up company Mitotherapeutix. Dr. James V. DeGregori is a Principal Investigator on the grant and on the animal protocol. Mitotherapeutix has developed peptides for an acute myeloid leukemia therapy that are used by James V. DeGregori’s in his research sponsored by National Cancer Institute.
Targeting MCJ/DNAJC15 and the mitochondrial electron transport chain in acute myeloid leukemia
Project Narrative Acute myeloid leukemia (AML) is the most common acute leukemia in adults and comprises 20% of childhood leukemias. While there has recently been considerable progress in treating other types of leukemia, progress in improving therapy for AML has been slow and survival rates for most patients remain quite low. Thus, there is a great need for more effective and less toxic therapies for AML. Our recent studies have led us to identify a new molecule called MCJ with low expression in some AMLs. Our collaborators have developed novel MCJ agonists that can restore function in cancer cells lacking MCJ. The goal of this proposal is to investigate whether MCJ agonists can be used to treat AML cells in vitro and in vivo. MCJ agonists could emerge as novel therapies that can synergize with current targeted AML therapies and prevent relapses.
Filed on July 22, 2019.
Tell us what you know about James Degregori's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
James Degregori filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| James Degregori | University of Colorado Denver | Conflict of Interest | Mitotherapeutix | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.